Overview

A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and clinical efficacy of ultra-low-dose decitabine in Chinese MDS
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Azacitidine
Decitabine